![Kenzo Kosuda](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kenzo Kosuda
Direttore Finanziario/CFO presso REGiMMUNE Corp.
Provenienza dei contatti di primo grado di Kenzo Kosuda
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
REGiMMUNE Corp.
![]() REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan.
11
| Holding Company | Pharmaceuticals: Major | 11 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Kenzo Kosuda tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
Genentech, Inc.
![]() Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Director of Finance/CFO Corporate Officer/Principal | |
MERRILL LYNCH PREFERRED CAPITAL TRUST I | Major Banks | Corporate Officer/Principal | |
Cygnus, Inc.
![]() Cygnus, Inc. Medical SpecialtiesHealth Technology Cygnus, Inc. develops and manufactures glucose-monitoring devices. The company develops devices that provide data to individuals and physicians to enable them to manage diabetes. It was founded in 1985 and is headquartered in San Francisco, CA. | Medical Specialties | President | |
Roche Pharmaceuticals, Inc.
![]() Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Trellis Bioscience, Inc.
![]() Trellis Bioscience, Inc. BiotechnologyHealth Technology Trellis Bioscience, Inc. is discovers and develops novel human antibody therapeutics. It provides the discovery and development of therapeutic antibodies from human B cells. The firm develops the CellSpot antibody discovery platform, which enables the identification of antibodies directly from human blood. The company was founded by Lawrence Kauvar and Stote Ellsworth in 1998 and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member | |
Raven Biotechnologies, Inc.
![]() Raven Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Raven Biotechnologies, Inc. engages in the development of antibody therapeutics for the treatment for cancer, autoimmune disorders and infectious diseases. Its products are used in treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 and is headquartered in South San Francisco, CA. | Miscellaneous Commercial Services | Founder | |
Abmaxis, Inc.
![]() Abmaxis, Inc. Pharmaceuticals: MajorHealth Technology Abmaxis Inc. develops pharmaceutical drugs. The company discovers and optimizes monoclonal antibody (mAb) products for human therapeutics and diagnostics. It has developed antibody engineering technology platform, Abmaxis in-silico Immunization (AISIM TM), which they are used for building an internal product pipeline and collaboration with global biotech and pharmaceutical partners. The company was founded in 2000 and is located in Santa Clara, CA. | Pharmaceuticals: Major | President Corporate Officer/Principal | |
Stanford University | College/University | Masters Business Admin Graduate Degree | |
University of Washington
![]() University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Graduate Degree | |
Banyu Pharmaceutical Co. Ltd.
![]() Banyu Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Banyu Pharmaceutical Co. Ltd. produces and distributes pharmaceutical products. It researches, develops, manufactures, sells, and imports and exports ethical drugs in Japan. Banyu Pharmaceutical was founded in 1915 and is headquartered in Tokyo, Japan. | Pharmaceuticals: Major | Director/Board Member | |
RIKEN CORPORATION | Auto Parts: OEM | Corporate Officer/Principal | |
JAPAN ASIA INVESTMENT CO., LTD. | Investment Managers | Corporate Officer/Principal | |
Keio University | College/University | Graduate Degree | |
Smith College
![]() Smith College Other Consumer ServicesConsumer Services Smith College opened in 1875 with 14 students. Today, Smith is among the largest women’s colleges in Northampton, MA, with students from 48 states and 72 countries. The college remains strongly committed to the education of women at the undergraduate level, but Smith admits both men and women as graduate students. | College/University | Undergraduate Degree | |
Mitsui & Co. Global Investment, Inc.
![]() Mitsui & Co. Global Investment, Inc. Investment ManagersFinance Mitsui & Co. Global Investment, Inc. (Mitsui & Co. Global Investment) is a venture capital subsidiary of Mitsui Ventures founded in 1999. The firm is headquartered in Menlo Park, California. | Investment Managers | Private Equity Investor | |
Waseda University | College/University | Undergraduate Degree | |
Saitama University | College/University | Doctorate Degree | |
Nagoya University | College/University | Doctorate Degree Graduate Degree | |
University of Shizuoka | College/University | Doctorate Degree | |
GeneTrol Biotherapeutics, Inc. | Corporate Officer/Principal | ||
DNAX Research, Inc. | Corporate Officer/Principal | ||
CBYON, Inc. | Director of Finance/CFO | ||
University of Tsukuba | College/University | Graduate Degree | |
The Japanese Society for Immunology | Corporate Officer/Principal | ||
La Jolla Institute for Allergy & Immunology
![]() La Jolla Institute for Allergy & Immunology Miscellaneous Commercial ServicesCommercial Services La Jolla Institute for Allergy & Immunology is a non-profit organization located in La Jolla, CA. The private company focuses on immunology research and aims to unravel the complexities of the immune system to tackle an array of diseases such as asthma, cancer, COVID-19, type 1 diabetes, and Parkinson's. The company is home to three research centers that focus on autoimmune conditions, cancer, and infectious diseases. The company offers various services such as bioinformatics, clinical studies, cryo-em, flow cytometry, histopathology, immunometabolism, microscopy & histology, and next-generation sequencing. The company also provides licensing opportunities and initiatives. The company was founded by Steve Pontell and is currently led by Erica Saphire as the CEO. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
ProtElix, Inc. | Corporate Officer/Principal | ||
PROMETHERA Biosciences SA
![]() PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
A-CUBE, Inc.
![]() A-CUBE, Inc. BiotechnologyHealth Technology A-CUBE, Inc. develops novel antibodies. It utilizes silico algorithms and to discover novel druggable targets suitable for developing human therapeutic interventions, including next generation drugs for commercially proven targets. The company was founded by Nobuyuki Ota is headquartered in Belmont, CA. | Biotechnology | Director/Board Member | |
Tokyo University of Science | College/University | Graduate Degree | |
RAQUALIA PHARMA INC. | Pharmaceuticals: Major | Director/Board Member | |
NapaJen Pharma, Inc.
![]() NapaJen Pharma, Inc. Pharmaceuticals: MajorHealth Technology NapaJen Pharma, Inc. develops drug delivery technology solutions through cellular transport pathways. Its products include lead platform and drug delivery. The firm specializes in the development of novel drug delivery systems by utilizing natural transport pathways whose cells are used to move molecular cargo into themselves and across internal compartments. The company was founded by Dr. Kazuo Sakurai and Hironori Ando in December 2004 and is headquartered in Burlingame, CA. | Pharmaceuticals: Major | Director/Board Member | |
Lexwell Partners | Founder | ||
PRISM BioLab Co., Ltd.
![]() PRISM BioLab Co., Ltd. BiotechnologyHealth Technology PRISM Pharma Co., Ltd. operates as a pharmaceutical company that focuses on discovery and development of small molecules to modulate protein-protein interactions. It utilizes protein secondary structure mimetic library, which modulates intracellular protein and protein interactions. The firm develops an anti-cancer drug CP/Catenin inhibitor PRI-724 that acts on both cancer cells and cancer stem cells that can switch from proliferation to differentiation. The company was founded by Hiroyuki Kouji on November 2, 2006 and is headquartered in Fujisawa, Japan. | Biotechnology | Director/Board Member | |
MIT Sloan School of Management | College/University | Masters Business Admin | |
Miyako Capital KK
![]() Miyako Capital KK Investment ManagersFinance Miyako Capital KK (Miyako Capital) is an Independent Private Equity/Venture Capital firm founded in 2013 by Satoshi Yamaguchi and Hiroaki Okahashi. Miyako Capital KK is headquartered in Kyoto. | Investment Managers | Private Equity Investor | |
Okinawa Protein Tomography Ltd.
![]() Okinawa Protein Tomography Ltd. Miscellaneous Commercial ServicesCommercial Services Okinawa Protein Tomography Ltd. provides polymeric molecular structure analysis services. Its technology allows imaging of macromolecules including proteins in multiple states at the single molecule-level by combining conventional electron tomography and a specifically designed 3D reconstruction program known as COMET. The firm analyzes data of molecular structures of protein samples. The company was founded by Akira Kamei on June 25, 2014 and is headquartered in Uruma, Japan. | Miscellaneous Commercial Services | Director/Board Member | |
DCI Partners KK
![]() DCI Partners KK Investment ManagersFinance DCI Partners KK (DCI Partners) is a venture arm of Daiwa Corporate Investment Co., Ltd. founded in 2014. The firm is headquartered in Tokyo, Japan. | Investment Managers | Director/Board Member | |
FUNPEP COMPANY LIMITED | Biotechnology | Founder | |
NOILE-IMMUNE BIOTECH INC. | Pharmaceuticals: Major | Director/Board Member | |
ARTham Therapeutics, Inc.
![]() ARTham Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Kaken Pharmaceutical Co., Ltd., ARTham Therapeutics, Inc. is a pharmaceutical company based in Yokohama, Japan. The Japanese company's mission is to deliver "medicines that matter" to improve patient health and contribute to enhanced quality of life through the development of innovative disease-modifying medicines. The company was founded by Sham Nikam, Naoto Uemura, and has been led by CEO Hiroshi Nagabukuro since 2018. ARTham Therapeutics was acquired by Kaken Pharmaceutical Co., Ltd. on December 13, 2021 for $111.95 million. | Pharmaceuticals: Major | Director/Board Member | |
Junten Bio Co. Ltd.
![]() Junten Bio Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Junten Bio Co. Ltd. is a Japanese company founded in 2018 that engages in research and development of cell and regenerative medicines. The company is based in Chuo-ku, Japan. | Miscellaneous Commercial Services | Director/Board Member | |
Clearview Projects, Inc. | Corporate Officer/Principal | ||
KIDSWELL BIO CORPORATION | Biotechnology | Director/Board Member | |
TMS CO., LTD. | Miscellaneous Commercial Services | Director/Board Member |
Statistiche
Distribuzione geografica
Stati Uniti | 26 |
Giappone | 24 |
Corea del Sud | 2 |
Belgio | 2 |
Settori
Health Technology | 16 |
Consumer Services | 12 |
Finance | 9 |
Commercial Services | 7 |
Health Services | 2 |
Posizioni
Director/Board Member | 41 |
Corporate Officer/Principal | 23 |
Graduate Degree | 9 |
Independent Dir/Board Member | 7 |
President | 7 |
Contatti più connessi
- Borsa valori
- Insiders
- Kenzo Kosuda
- Connessioni Società